Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors.
Mitomycin C is an active drug in the treatment of superficial bladder cancer. Although clinical safety of intravesical mitomycin C has been well accepted there are no data on absorption of this drug from the bladder in patients with damaged bladder mucosa. We studied 18 patients for evidence of absorption of mitomycin C after transurethral resection and/or radiation therapy. Mitomycin C is absorbed on intravesical instillation and the degree of absorption depends on the degree of damage to the bladder. Despite some evidence of absorption no systemic effect on bone marrow was observed and no evidence of deoxyribonucleic acid damage was found in any of these patients. Mitomycin C appears to be a safe drug but further studies are indicated to document its safety when used for maintenance therapy.
D000903:Antibiotics, Antineoplastic / Q000378:metabolism* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000378:metabolism / Q000628:therapy; D003131:Combined Modality Therapy; D004247:DNA / Q000378:metabolism; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000378:metabolism* / Q000627:therapeutic use; D012854:Sister Chromatid Exchange / Q000187:drug effects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000628:therapy
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D016685:Mitomycin; D004247:DNA